Skip to main content
. Author manuscript; available in PMC: 2013 Jul 1.
Published in final edited form as: Prostate. 2011 Dec 7;72(10):1117–1123. doi: 10.1002/pros.22458

Fig. 4. 17-AAG prevention of LuCaP35 tumor progression to castration resistance.

Fig. 4

Serum PSA was measure to determine relapse of LuCaP35 tumors 5 weeks after castration, which was 1 week after the completion of 17-AAG or vehicle administration. A PSA value of 6 ng/ml, marked by the dotted line, is considered indicative of tumor relapse. Progression to castration resistance in the vehicle-treated group is statistically different from that in the 17-AAG-treated group according to Fisher’s Exact Test (*p < 0.02). Each group contained 17 animals.